ENVX: Held by 1 Biotech Hedge Fund (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Home›Companies›Enovix Corp (ENVX)

Enovix Corp

ENVX

Held by 1 specialist biotech fund

1 fund opened new positions. Short interest: 27.1% of float.

Electrical Equipment & PartsCEO: Ryan A. BentonIPO: 2021Website ↗

Founded in 2007 and based in Fremont, California, Enovix Corporation specializes in the innovation, development, and production of lithium-ion battery technology.

Score Holdings Short Interest Catalysts Insiders Research

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback

Signal Score

3.5/10

1 fund opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 1 specialist fund●●

See how each signal contributes — fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Driehaus Capital

Position history (shares)

Driehaus Capital

AI Signal

Signal Note: Driehaus Capital Exits ENVX

Growth-focused Driehaus has fully exited Enovix (solid-state battery developer for EVs/consumer electronics), eliminating what was a material biotech allocation position. The exit signals either deteriorating confidence in commercialization timing for its anode-free cell technology or reallocation pressure within their growth portfolio—particularly relevant given ENVX's cash runway constraints typically require capital raises ahead of meaningful revenue inflection.

Unlock full AI analysis — 14-day free trial

4 quarters

Position Trend

Nov 14, 2025

$8.0M

1 fund

Feb 17, 2026

0 funds

May 15, 2026

0 funds

Aug 14, 2026

0 funds

-100% total institutional value over 13 quarters

Short Interest

SI rising 2 periods (+7%)

Short Shares

53.06M

Change

-1.1%

Days to Cover

7.8

% of Float

27.1%

Settlement

Sep 30, 2026

Short interest over 12 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Driehaus CapitalEXITEDAug 14, 2026

Start free trial for share counts, dollar values & AI analysis

12 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

VSECU1 fund WYFI1 fund PBLS1 fund TWST1 fund ULS1 fund CUBB1 fund DFTX1 fund GFIOF1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer